Satellite Symposia webcasts

Treatment Considerations for Advanced NSCLC: Now and in the Future 

Boehringer Ingelheim

• Introduction
  Byoung Cho
• Navigating first-line treatment decisions for EGFRM+ NSCLC: Extrapolating from Asian clinical trial experience
  John Wen-Cheng Chang
• Tackling Uncommon EGFR mutations: Efficacy of EGFR TKIs in NSCLC
  Hiroshi Tanaka
• KRAS-mutant NSCLC treatment advances on the horizon
  Byoung Cho
• Closing
  Byoung Cho
• Live Q&A

The role of immuno-oncology in the evolving treatment landscapes of upper GI cancers

Bristol Myers Squibb

• The role of immuno-oncology in the evolving treatment landscapes of upper GI cancers
  Matthew Ng, Kohei Shitara, Chih-Hung Hsu, Ka-On Lam
• Live Q&A
  Matthew Ng, Kohei Shitara, Chih-Hung Hsu, Ka-On Lam

Expanding the horizon for the treatment of solid tumors with antibody drug conjugates (ADCs)

Daiichi Sankyo

• Welcome and introduction
  Tony S.K. Mok
• How are technologically advanced ADCs expanding the horizon for the treatment of solid tumours?
  Tony S.K. Mok
• Expanding the horizon for the treatment of breast cancer with ADCs
  Rebecca Dent
• Expanding the horizon for the treatment of lung cancer with ADCs
  Keunchil Park
• Expanding the horizon for the treatment of colorectal and gastric cancer with ADCs
  Hyun Cheol Chung
• Live Q&A + summary and close
  Tony S.K. Mok, Rebecca Dent, Keunchil Park, Hyun Cheol Chung

Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

Pfizer

• Opening remarks and introduction
  Ross A. Soo
• Dissecting the molecular differences and clinical outcomes of EGFR patients with Exon 19 deletion and Exon 21 L858R mutations
  Yi-Long Wu
• Case based discussion
  Ullas Batra
• Panel discussion and closing
  Ross A. Soo, Yi-Long Wu, Ullas Batra, Nellie Cheah Lay Chin

Clinical Evidence to Real-World Experience: Bridging the Best of Both Worlds in the Management of ER+ HER2- mBC

Pfizer

• Introductory note
  Tira Tan
• Optimizing patient care in HR+/HER2- mBC in present times
  Adam Brufsky
• Real-world evidence of palbociclib & treatment approach in Asian patients
  Shaheenah Dawood
• Q&A and Closing
  Adam Brufsky, Shaheenah Dawood, Tira Tan

Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan-Tumour Perspective

Physicians' Education Resource

• Leveraging Novel Antibody-Drug Conjugates in a World of Evolving Treatment Paradigms: A Pan-Tumour Perspective
  Masakazu Toi, Josep Tabernero, Maurice Pérol
• Post session Survey and Q&A Session
  Masakazu Toi

Optimization of treatment strategy in advanced pancreatic cancer for Asian patients

Servier

• Introduction
  Katsuhiko Uesaka
• From guidelines to daily practice: The European experience
  Sara Lonardi
• Pancreatic cancer in Japan: from the current to the potential future treatment landscape
  Masafumi Ikeda
• From current to potential pancreatic cancer treatment landscape in China
  Liwei Wang
• Experience from daily practice with a new treatment option in Korea
  Changhoon Yoo
• Live panel discussion: Practice sharing from Europe to Asi a and Conclusions
  Julien Taieb, Katsuhiko Uesaka, Sara Lonardi, Masafumi Ikeda, Liwei Wang, Changhoon Yoo